Hs-10582

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

5 competitors in Dyslipidemia

#DrugCompanyPhaseTrials

1

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

42

Xuezhikang

Luye Pharma Group Ltd.

Phase 3

33

AZD4954

AstraZeneca

Phase 1

14

HRS-5632

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 1

—5

Hs-10582

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1

16

Pueraria Lobata

JJiangxi University of Traditional Chinese Medicine

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Dyslipidemia1 trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 Tablets After Single and Multiple Oral Doses in Healthy Subjects and Subjects With Mildly Elevated LDL-C

Not yet recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07777003·76 enrolled

Details

Drug Info

Related News